Growth / Performance
HGH-Frag 176-191
C₇₈H₁₂₃N₂₃O₂₃S₂
Key Research Findings
- Stimulates lipolysis in isolated adipocytes without affecting glucose or insulin metabolism.
- Does not raise serum IGF-1 — a key distinction from full-length HGH.
- Obese animal models show body fat reduction without the hyperglycaemic effects of native GH.
- Possible utility in bone metabolism research, with studies showing cartilage and bone effects.
Overview
HGH-Fragment 176–191 is a stabilised analogue of the C-terminal fragment of human growth hormone, encompassing amino acids 176 to 191. It was developed to isolate the lipolytic domain of HGH, providing fat metabolism research activity without the growth-promoting, diabetogenic, or mitogenic effects of the full molecule.
Mechanism of Action
HGH-Frag 176–191 stimulates lipolysis and inhibits lipogenesis through mechanisms similar to full-length HGH acting on adipose tissue, but does so without binding the IGF-1 receptor or raising circulating IGF-1. This selective action on fat metabolism is attributed to a separate lipid-regulating domain within the HGH C-terminus.
Research Effects
Fat Metabolism
Extensive ResearchIn vitro and animal evidence consistently shows HGH-Frag stimulates lipolysis in adipocytes, specifically targeting fat breakdown without full GH side effects.
Metabolic Regulation
Moderate ResearchResearch demonstrates improved body composition in obese animal models without disruption of glucose homeostasis.
Anti-obesity
Moderate ResearchAnimal studies show selective fat mass reduction, underpinning its utility in metabolic research.
Bone & Cartilage
Preliminary ResearchEarly in vitro studies suggest HGH-Frag may support chondrogenesis, warranting further in vivo investigation.
Research Purposes Only — All information on this page is provided for scientific research purposes only. This product is not intended for human consumption, diagnosis, treatment, or prevention of any disease.
Quick Facts
Research Status Key
Related Peptides
Cellular / Energy
AOD-9604
AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH 176–191), developed to isolate the lipolytic properties of HGH without its mitogenic or diabetogenic effects. It is studied for its potential role in fat metabolism and metabolic regulation.
Learn More →
Growth / Performance
CJC-1295 (No DAC)
CJC-1295 without DAC (also known as Modified GRF 1–29 or Mod GRF 1–29) is a 29-amino acid analogue of growth hormone-releasing hormone (GHRH). It contains four amino acid substitutions that increase its stability and receptor affinity compared to native GHRH, while the absence of the Drug Affinity Complex (DAC) preserves a shorter, more physiological half-life.
Learn More →
Growth / Performance
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist (GHSR-1a) consisting of 5 amino acids. It is studied for its highly selective GH-releasing properties, producing significant GH pulses without the concomitant cortisol, prolactin, or ACTH release seen with first-generation GHRPs.
Learn More →